# Humanis Accelerates Global Expansion: After China, the Next Target Is the U.S. Market

> Humanis, the first Turkish company to export pharmaceuticals to China, is strengthening its global presence with a robust R&D infrastructure and a sustainability-driven growth strategy. The company has now set its sights on entering the U.S. market within the next 5 years, marking a critical milestone in its international expansion journey.

Published: 2026-04-17T11:11:00+00:00
Language: en
Categories: [Pharmaceutical Industry](https://chemexworld.com/en/categories/sectors/pharmaceutical-industry-1.md)

Canonical URL:
https://chemexworld.com/en/news/humanis-next-target

## Content

**Humanis**, a subsidiary of Saya Holding and one of Turkey’s top 500 industrial enterprises, is setting its sights on the U.S. market after becoming the first Turkish pharmaceutical company to export to China. Targeting **$250 million in revenue** and a production volume of **120 million units for 2025**, the company has initiated a five-year strategic roadmap to enter the American market under FDA standards.

### **Powering 1 in 20 Medicines in Turkey**

Since starting production in 2013, Humanis has rapidly scaled to account for **1 out of every 20 boxes of medicine** produced in Turkey. With a robust export network spanning Europe, the Middle East, Central Asia, and Africa, the company holds prestigious **EU GMP** and **Canada GMP** certifications. Its European operations are further strengthened by **Humanis GmbH**, established in Germany to ensure a direct and sustainable presence in the EU.

### **The China Milestone: A Springboard for the U.S.**

Having cleared the high regulatory hurdles of the Chinese market, Humanis is now re-engineering its R&D and operational infrastructure for the United States. By aligning its quality, traceability, and validation processes with **FDA (U.S. Food and Drug Administration)** requirements, the company views this move not just as an export expansion, but as a total transformation of its global manufacturing standards.

### **Top 5 R&D Hub in Europe**

At the heart of this growth lies the **2,500-square-meter R&D Center** in Çerkezköy, which ranks among the top five largest facilities of its kind in Turkey and Europe. Leveraging this technical prowess, Humanis:

- Manages over **200 licensed products** across **12 therapeutic areas**.
- Is preparing to enter the **oncology and diabetes** sectors within the next three years.
- Contributes **400 million TRY annually** to public finances through innovative treatments for rare diseases (such as CTX).

![](https://chemexworld.com/storage/uploads/cem_mengi.jpg)

### **Sustainable Growth Through Green Energy**

Beyond production metrics, Humanis is setting industry benchmarks for sustainability. Following an **$8 million investment in Solar Power Plants (GES)**, the company now meets **70% of its energy needs** through solar power. Additionally, it has achieved a remarkable **74% recycling rate** across its operations.

> **At Saya Holding, we have established a resilient structure by integrating pharmaceuticals, real estate, and defense technologies within the same strategic framework. We are not just managing today; we are preparing for tomorrow’s risks through sustainable growth."** > — *Cem Mengi, Chairman of the Board, Saya Holding*